Skip to main content

Biotech's a Buy, but Hold Off on HMOs: Fund Manager

Rock bottom interest rates will likely boost key stocks in the biotechnology sector, a fund manager told CNBC on Wednesday, but complex new healthcare implementation may cast a pall on the shares of health management organizations.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.